Evogene Ltd. EVGN
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $3.85M, -30.9% YoY · Filed Mar 26, 2026
Evogene Ltd. (EVGN) files with the SEC under industry code 2870, Agricultural Chemicals. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $3.9 million and a net loss of $7.8 million. Free cash flow was -$13.6 million. As of Dec 31, 2025 it held $13.0 million in cash and investments and $2.2 million in total debt.
Revenue
$3.85M
-30.9% vs prior year
Net income
$-7.83M
+56.6% vs prior year
Operating cash flow
$-13.50M
+31.5% vs prior year
Free cash flow
$-13.64M
+32.9% vs prior year
EPS
$1.08
+137.2% vs prior year
Dividend per share
None
Shares outstanding
8.72M
+33.8% vs prior year
Net cash
$10.76M
FY 2025
Operating margin
-364.2%
FY 2025
Company profile
- Industry
- Agricultural Chemicals (SIC 2870)
- Listed as
- EVGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Rehovot, Israel
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1574565
Other Agricultural Chemicals companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $3.9M | $5.6M | $3.0M | $1.7M | $930,000 |
| Operating income | -$14.0M | -$18.8M | -$22.2M | -$26.9M | -$31.0M |
| Net income | -$7.8M | -$18.1M | -$26.0M | -$29.8M | -$30.4M |
| Diluted EPS | $1.08 | -$2.90 | -$5.20 | -$6.44 | — |
| Operating cash flow | -$13.5M | -$19.7M | -$21.6M | -$23.7M | -$24.7M |
| Free cash flow | -$13.6M | -$20.3M | -$22.2M | -$24.8M | -$25.6M |
| Total assets | $20.0M | $39.9M | $51.1M | $56.1M | $76.3M |
| Total liabilities | $8.1M | $25.0M | — | — | — |
| Stockholders' equity | $12.0M | $14.8M | $28.7M | $34.8M | $63.4M |
| Cash and investments | $13.0M | $15.3M | $20.8M | $29.0M | $32.3M |
| Total debt | $2.2M | $2.5M | $1.1M | $1.8M | $2.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 28, 2026 | Oct 28, 2026 |
| 6-K | Current report (foreign issuer) | Oct 6, 2026 | Oct 6, 2026 |
| 6-K | Current report (foreign issuer) | Sep 30, 2026 | Sep 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 28, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Sep 15, 2026 | Sep 15, 2026 |
| 6-K | Current report (foreign issuer) | Sep 4, 2026 | Sep 4, 2026 |
All 463 Evogene Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.